Chang Chen

Shanghai Changchen Pharmaceutical is a clinical-stage biopharmaceutical company based in Shanghai, China, dedicated to the discovery and development of novel small molecule drugs. The company primarily targets metabolic disorders and oncology, with a focus on high-prevalence conditions with limited treatment options. Its lead candidate, CC-001, is a highly selective URAT1 inhibitor designed for the treatment of chronic gout and hyperuricemia, currently undergoing Phase 2 clinical trials. Founded by industry veteran Dr. Chang Chen, the firm leverages its internal research capabilities to advance a pipeline of differentiated therapeutic assets. Changchen Pharmaceutical has secured significant backing from prominent venture capital firms to support its clinical programs and expansion.